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Abstract 
While diagnoses of depression and anxiety are not uncommon for women during pregnancy and 
after delivery, one of the greatest challenges in the plan of treatment is to ensure that the 
offspring are kept safe while the psychological well-being of the mother is appropriately cared 
for. The objective of this literature review is to evaluate the commonly prescribed treatment 
methods for prenatal and postnatal depression, focusing on the efficacy of antidepressant 
medications and nonpharmacologic treatments while evaluating the effects these medications 
have on the fetus/breastfeeding infant. The method of research included 15 studies completed 
with within the past ten years on women who were pregnant or who had delivered a baby within 
the past 12 months. One study did evaluate long-term effects on offspring, which included a 
participant number of 3,342 children who were exposed to antidepressants during pregnancy. 
Two Cochrane Review evaluations were also included in this research. The total number of 
participants in the studies were 8,069 women. Limitations of the results were due to small 
sample sizes in several of the studies and few studies available that directly evaluate this 
population of women and children. The compiled data results suggest that while cognitive group 
therapy does provide depression symptom improvement in prenatal and postnatal depression and 
anxiety, antidepressant medications tend to have a positive effect earlier in treatment. 
Unfortunately, many of these antidepressant medications have also been proven to have both 
short and long tern effects on the offspring exposed to pharmacologic treatment. 
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Introduction 
Within the primary care practice, providers have many opportunities to care for patients 
with anxiety and depression diagnoses. Not only are solid relationships built between the 
provider and patient, but there are also the important aspects of trust and rapport that aide in the 
effective management of mental health disorders. According to the National Guideline 
Clearinghouse guideline summary, first line treatment for severe or chronic major depression 
disorder as diagnosed by the Patient Health Questionnaire-9 (PHQ9) screening, is a referral to 
behavioral health in combination with antidepressant therapy (2012). Guideline 
recommendations for the general adult population suggest that any class of antidepressants are 
first-line treatment options such as: selective serotonin reuptake inhibitor (SSRI), tricyclic 
antidepressants (TCA), serotonin-norepinephrine reuptake inhibitor (SNRI), norepinephrine 
reuptake inhibitor (NRI), and dopamine agonists (DA) (National Guideline Clearinghouse, 
2012).  
One difficult area in the treatment of both depression and anxiety is in the prenatal and 
breastfeeding patient population. Unfortunately, research has shown that the prevalence of 
depression during pregnancy and the postpartum time are quite high. During pregnancy, the 
prevalence of depression appears to be in the spectrum of 6-13% (Charlton et al., 2014) and 
possibly up to 15% (Van Lieshout et al., 2017). When considering the prevalence of depression 
and anxiety throughout pregnancy, research has shown an increase in stress levels at 16 weeks of 
gestation and again towards the end of pregnancy, which correlated with elevated depression 
scores at this time (Rallis et al., 2014). After delivery, the incidence increases to almost 20% 
(Van Lieshout et al., 2017). 
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Providers and patients must work together to determine the best path of action for this 
unique situation of caring for both the pregnant patient's mental health and her unborn child.  
This scholarly project primarily focuses on the mental health aspect of prenatal care and the cost-
to-benefit considerations included when choosing a treatment option. Two main options are 
considered, including pharmacologic treatment and behavioral therapy which will be evaluated 
on both effective management of the mother’s psychological state as well as provision of a safe 
environment for the unborn child.  
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Statement of the Problem 
One difficult area in the treatment of both depression and anxiety is in the prenatal and 
breastfeeding patient population. Providers and patients must work together to determine the best 
path of action for this unique situation of caring for both the pregnant patient's mental health and 
her unborn child.   
Research Questions 
In the pregnant and breastfeeding population, what is the efficacy of antidepressant 
medication treatment for patients diagnosed with depression and/or anxiety? 
In pregnant patients diagnoses with depression and/or anxiety, what are the fetal effects 
resulting from use of antidepressants during pregnancy? 
In breastfeeding patients diagnosed with depression and/or anxiety, are there effects 
caused from the transfer of antidepressant medications from mother to infant during lactation? 
In patients diagnosed with depression and/or anxiety during pregnancy and postpartum, 
what is the effectiveness of treatment options such as cognitive behavioral health therapy? 
The Introductory section stated above brings awareness to the increased rate of 
depression during pregnant and postpartum women, which is a challenging factor for providers 
and patients to manage effectively and safely. In stating the research questions above, the 
upcoming literature review will delve deeper into the current research available on 
pharmacological and nonpharmacological treatment for the diagnosis of depression in pregnancy 
and postpartum. Within the Discussion section, a review and comparison of the research findings 
will provide a platform for the current data on treatment of depression in women of childbearing 
age who are either pregnant or breastfeeding. 
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Methods 
The collection of research and data for this scholarly project included a specific study 
population of women within childbearing ages eighteen to forty years old who were either 
pregnant or breastfeeding during the time of the study. The research was selected first by 
randomized clinical trials within the past ten years in order to ensure recent data collection 
throughout the literature found from PubMed, PsychINFO, Cochrane, and PsychiatryOnline. The 
selection criteria for subjects as stated above was quite specific to women who were currently 
pregnant or breastfeeding, but did include research completed outside of the United States to 
gain more of an international, unbiased perspective. 
The research methods used consisted of data collection from PubMed, PsycINFO, 
Cochrane Review, and PsychiatryOnline. First, a search was completed on PubMed to include 
the keywords of “Pregnancy AND depression.” 874 results were found and were then filtered by 
clinical study within the past ten years. Finally, irrelevant studies were excluded that did not 
include depression or pregnancy after which two results were found to use in this research. My 
next search was of the subject heading “prenatal depression” with a keyword of “treatment”. 
When filtered again by date and study, there were twenty-four results. The links were evaluated 
and two studies directly relating to depression during pregnancy were used for this research. The 
next search focused on anxiety treatment in pregnancy using the keywords of “pregnancy,” 
“anxiety,” and “treatment”. Again, results were filtered by a date of recent ten years and included 
comparative and multicenter studies with human subjects. This resulted in 121 links, which were 
reviewed and five results directly relating to pregnancies without comorbidities were found. The 
studies excluded did not pertain to depression treatment options and those studies that included 
patients with multiple comorbidities. The final search included keywords, “Antidepressants, 
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pregnancy AND postpartum, AND effectiveness.” Filters were applied to include randomized 
control trials in the past ten years. Three search results were present, with one link evaluating the 
effectiveness of pharmacotherapy in comparison to psychosocial intervention which was added 
to the list of sources for this project. 
PsycINFO was the next database searched. The initial filter set was a past date of 10 
years. The first search completed was with the keywords “depression treatment in pregnancy.” 
The result was 204 links with only one final study directly correlating to depression treatment 
with serotonin reuptake inhibitors (SSRIs) in pregnancy. The keywords “pregnancy, depression, 
pharmacology, behavioral therapy” were used in the next search with a filter of human subjects. 
Ten results appeared, and were filtered by continuing studies or unrelated research, and one link 
was added to relevant research. The next search included the keywords “pregnancy, depression, 
anxiety.” There were fifty-two links and the topics not relating to perinatal treatment were 
excluded, with one result added to the research. The final search was with keywords “pregnancy, 
depression AND SSRI benefits” for studies within the past 10 years in qualitative study form. 
There were seven results, with one result evaluating the effectiveness of SSRI use during 
pregnancy. 
Within Cochrane Review, the first search included “Antidepressant use in pregnancy” 
and came up with five results. Within these five results, one review focused on SSRI use in 
postnatal depression. When the search was widened to “Antidepressants, pregnancy,” six results 
were present, with the one other result focusing on antidepressant use in pregnancy as a proposed 
protocol which was not applicable to this research project. 
A search on PsychiatryOnline was next completed using keywords, “antidepressants, 
pregnancy, effectiveness.” Once filtered to contain the past ten years in the category of 
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“Antidepressants,” thirty-one results were present. Of these results, one study related specifically 
to comparison of untreated depression and antidepressant use in pregnancy which was added to 
the list of sources for this project. 
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Literature Review 
As explained above in the Methods section, the study population for this research focused 
on women ages 18-42 who were either pregnant, recently delivered, or breastfeeding during the 
time of the study. Once collected, the data was then categorized according to the research topic. 
The focus of this research project evaluates four key themes. The first two specifically evaluate 
antidepressant medication effectiveness during pregnancy and postpartum an assess the effects 
the medications have on fetal development and growth long-term. The next theme was to 
evaluate antidepressant medication transfer to the infant during lactation. Finally, the next 
category of data collection evaluates the effectiveness of cognitive behavioral therapy for 
management of anxiety and depression, during both the prenatal and postpartum timeframes. 
Depression and Pathophysiology of Antidepressant Medications 
As stated above in the Introduction, depression and anxiety during pregnancy and 
postpartum is not an uncommon occurrence for women. Depression symptoms are hypothesized 
to be caused by a deficiency of synaptic neurotransmitters such as serotonin, norepinephrine, and 
dopamine (Bardal et al, 2011, p. 369). Specific criteria within the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM V) states specific symptom criteria in a 2-week 
period that signifies a change from previous functioning ability. At least one of the symptoms 
must be a depressed mood or loss of interest/pleasure (American Psychiatric Association (2013). 
As shown below in the literature review studies, there are multiple certified screening tools 
available to clinicians to evaluate for the presence of depression.  
When discussing postnatal depression, the diagnostic criteria is the same as non-
pregnancy related depression. According to CURRENT Diagnosis and Treatment: Obstetrics & 
Gynecology by Decherney, Nathan, Laufer, and Roman (2013), postpartum depression 
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specifically is characterized by, “Depression that begins in the 12 months after delivery… 
symptoms must be present nearly every day for at least two weeks” (p. 367). 
The methods of action for antidepressants vary on the type of medication used but all 
work to improve the mood in diagnosed depression. Specifically, in this collection of research, 
SSRIs are the primary class of antidepressants prescribed, followed by SNRIs and then 
bupropion.  SSRI medications (examples include fluoxetine, paroxetine, fluvoxamine, sertraline, 
citalopram, and escitalopram) act by binding to the serotonin reuptake transporter, thereby 
inhibiting the reuptake of serotonin in the synaptic cleft and increasing the amount of serotonin 
available to bind to the postsynaptic receptors (Bardal et al, 2011, p. 369). SNRI medications 
(venlafaxine, desvenlafaxine, duloxetine, milnacipran, etc.) work by a slightly different 
mechanism of action and increase the available concentration of both serotonin and 
noradrenaline within the synaptic cleft (Bardal et al., 2011, p. 373). Bupropion is in the class of 
atypical antidepressants, noradrenaline and dopamine reuptake inhibitors (NDRIs). The 
mechanism of action for bupropion is to inhibit the presynaptic reuptake of dopamine and 
noradrenaline which leads to an increased availability of both neurotransmitters in the synaptic 
cleft (Bardal et al., 2011, p. 378). The treatment effectiveness of antidepressant medications 
typically take several weeks for results to be present. These different classes of medications are 
primarily noted in the following studies. 
Introduction to Themes 
 Within the scope of this literature review, an assessment of current practices using 
antidepressants and nonpharmacologic means of treating depression will be completed. The 
efficacy of antidepressant medications will be evaluated during both pregnancy and postpartum. 
Next, the effects of antidepressant medications on the fetus will be reviewed, along with effects 
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on the infant during lactation. Finally, the effectiveness of nonpharmacologic treatment methods 
such as therapy sessions will be evaluated for the management of depression during pregnancy 
and postpartum. 
Theme A: antidepressant pharmacotherapy efficacy during pregnancy and 
postpartum 
The study completed by Charlton et al. (2014) in Europe intended to closely observe the 
correlation between SSRI’s prescribed before, during, and after pregnancy. This was a large, 
population-based study that included 721,632 participants and 86,943 deliveries with information 
collected through data collection through databases. Six electronic healthcare databases 
throughout Europe were used to include pregnancy and prescription information from January 1, 
2004 to December 31, 2010. The Denmark database collection ended on December 31, 2009. 
Women were included in the study who had been present in the database with the necessary data: 
prescription records one year prior to the pregnancy through one year after pregnancy. The 
SSRIs in the study specifically included fluoxetine, citalopram, paroxetine, sertraline, 
fluvoxamine, and escitalopram (Charlton et al., 2014). 
Results from the study found that prescriptions for SSRIs in the second and third 
trimesters were markedly lower compared to pre-pregnancy and first trimester, but then 
increased again in the postpartum period after delivery. Of all the deliveries, 5.4% [95% 
confidence interval (CI95), 5.3-5.4%] of the women were found to have received a prescription 
for an SSRI in the year leading up to pregnancy. During pregnancy, however, the use of SSRIs 
fell to 2.3% (CI95, 2.2-2.3%). The percent of individuals with an SSRI prescription prior to 
pregnancy decreased upon determination of pregnancy, with at least 40% discontinuing their 
prescription during pregnancy. In the year after pregnancy, SSRI prescriptions were noticeably 
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higher in the United Kingdom databases compared with the other four, however, by six months 
postpartum, prescription SSRIs returned to the pre-pregnancy levels stated above (Charlton et al., 
2014).  
A prospective observational study by Wisner et al. (2009) evaluated the effects of major 
depression and antidepressant treatments in pregnancy and neonatal outcomes. The study 
completed maternal evaluations at gestation weeks 20, 30, and 36. There were 381 pregnant 
women, ages 15-44 years old, categorized into separate groups: no SSRI use and no depression, 
continuous SSRI exposure, partial SSRI exposure, continuous MDD with no SSRI use, and a 
fifth group of women with partial MDD with no SSRI exposure (MDD for at least part of the 
pregnancy). Women who reported alcohol abuse or dependence were excluded from the study. 
Severity of the participant’s depression was evaluated using the Structured Interview Guide for 
the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS). 
Outcomes of the research focused on SSRI treatment effectiveness and neonatal effects which 
will be explained below in Theme B (Wisner et al., 2009). 
Results from the research found that of the 381 participants, 238 were eligible and 
provided the necessary neonatal outcome data. In the evaluation of subjects, data showed that 
women who were in the group with continuous MDD and no SSRI treatment during pregnancy 
reported more alcohol use (more than one drink per week or binge drinking) than either of the 
groups receiving SSRI treatment and the group categorized by no SSRIs and no depression. The 
most commonly prescribed SSRIs were sertraline (34%), fluoxetine (25%), and citalopram or 
escitalopram (23%). Several other treatment regimens included combination therapy which 
included an SSRI with bupropion or an SSRI with a tricyclic antidepressant (18%). It was found 
that the women not exposed to SSRIs and with no depression had lower depressive symptoms 
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and a higher functional status. The women with no SSRI exposure but diagnosed with MDD had 
a higher mean depressive symptom level when compared to all other groups. In relation to 
weight, SSRI use and depression were not related to maternal weight gain. Women with 
depression did have non-significantly higher mean pre-pregnancy body mass index (BMI) scores 
when compared to other subjects and tended to have a lower mean weight gain (Wisner et al., 
2009). 
A pragmatic two-arm individually randomized controlled trial by Sharp et al. (2010) 
evaluated the effectiveness of antidepressant therapy compared to psychosocial therapy in 
women diagnosed with postnatal depression (PND) using the International Classification of 
Diseases version 10 (ICD-10) criteria. Participants were from Bristol in south-west England, 
south London, and Manchester in north-west England. Women were recruited between January 
2005 through August 2007 if they had recently delivered a live birth, were living with their baby, 
and were over age eighteen. Exclusions were applied if the mother had a stillbirth/neonatal death, 
infant was over 26 weeks old, foster/adopted infants, women with psychosis, alcohol/drug abuse, 
or those who were already receiving depression treatment. There were 254 women participating 
in the study who were randomly assigned the treatment methods of antidepressant (usually a 
SSRI) or non-directive counseling (listening) sessions. At four weeks of treatment, women were 
allowed to receive the alternate treatment intervention if they wished. Evaluation of the 
treatment’s effectiveness was measured by the women’s satisfaction, perspective from the 
general practitioner prescribing the antidepressant, and the trained health visitor administering 
the listening sessions (Sharp et al., 2010). 
Evaluation of depression was scored according to the baseline Edinburgh Postnatal 
Depression Scale (EPDS) score, with a score of ≥13 suggesting depression. Therefore, to ensure 
TREATING PERI AND POSTNATAL DEPRESSION AND ANXIETY 16 
 
false positives were not missed, a baseline score of ≥ 11 was used to diagnose depression. The 
results of the study found that at four weeks of treatment, of the 106 women who were assigned 
to the antidepressant group with a baseline EPDS score of ≥13, 45% had improved to an EPDS 
score of ≤ 13. At eighteen weeks, the improvements appeared in 60 of the 90 responders (62%). 
In the comparison group receiving active listening, 20% showed improvement in their EPDS 
scores to ≤ 13 at four weeks. At eighteen weeks, 51% of the participants had improved. When 
this information was analyzed using Complier- Average Causal Effect (CACE), the difference in 
EPDS scored when comparing those taking an antidepressant versus those not was -4.2 (CI95 -6.8 
to -1.6). Eleven of the sixteen women interviewed at the conclusion of the study reported 
beneficial effects from taking the antidepressant medications. Four reported no effects from the 
medication, and one woman reported feeling angry and manic on the medication (Sharp et al., 
2010). 
A Cochrane Review by Molyneaux, Howard, McGeown, Karia, and Trevillion (2014) 
sought to evaluate the effectiveness of antidepressant therapy in postnatal depression in 
comparison to other forms of treatment such as social support and psychological intervention. 
Their method of data collection was to use the Cochrane Depression, Anxiety and Neurosis 
Group’s Specialized Register (CCDANCTR) which included relevant randomized controlled 
trials from The Cochrane Library, MEDLINE, EMBASE, and PsycINFO up through the date of 
July, 2014. Within the six trials, 596 participants were included. All of the studies had a 
controlled parallel group in their research (Molyneaux et al., 2014). 
 Results of this review were grouped by study design. Four of the studies compared SSRIs 
with a placebo. The SSRIs used were sertraline, paroxetine, and fluoxetine. Of these four studies, 
two of them also incorporated psychological therapy into the treatment groups. Three of the four 
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studies (total of 146 participants) found that the random assignment of women to the SSRI 
treatment group had an increased response and remission rate from depression when compared to 
the placebo group [response ratio (RR): 1.43%].  The other study did not evaluate response or 
remission rates. Another group within this Cochrane review included one study that compared 
antidepressant therapy with treatment as usual for the first four weeks which were then followed 
by listening visits. The data did show increased improvement rates in the antidepressant 
treatment group when compared the treatment-as-usual group. However, there did not appear to 
be a difference in the later follow-up when comparing antidepressant therapy and listening visits. 
In a specific study comparing sertraline with nortriptyline (a tricyclic antidepressant), there did 
not appear to be any difference in effectiveness. Through the data collection process, it was 
found that women using the SSRIs did tend to experience side effects from the medications 
(Molyneaux et al., 2014). 
Theme B: antidepressant pharmacotherapy and fetal effects 
A population-based cohort study was completed by Handal et al. (2016) in Norway which 
evaluated the effects of SSRI treatment during pregnancy and the relationship to motor 
development in children. The method of study included pregnant women from 1999-2008 which 
included 51,404 children and 45,003 mothers. Using an Ages and Stages Questionnaire (ASQ), 
fine and gross motor skill questionnaires were completed by mothers three years after delivery 
and were then averaged to find the score.  Interestingly, only 3.5% of the children had an ASQ 
score that was greater than three which suggested clinical significant fine motor impairment, 
however the children exposed to SSRI’s in pregnancy had a slightly higher percentage compared 
to children who were not exposed with a 95% CI of -0.2 to 4.4%. There was also a shift towards 
delayed motor development found with exposure to SSRI with a stronger shift correlating to 
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increased exposure to SSRI use (Handal et al., 2016). Within the discussion section, Handal et al. 
(2016) found, “In this large prospective cohort study we found that treatment with SSRIs during 
longer periods of pregnancy was weakly associated with a delay in both fine and gross motor 
development in children aged 3 years” (p. 1914).  
A study by Hannerfors et al. (2015) compared the levels of corticotropin-releasing 
hormone (CRH) in depressed pregnant women receiving SSRI medications and those not. 
Specifically, the study assessed second trimester CRH serum concentration levels on women 
who were pregnant compared to depressed women not on SSRIs and healthy controls. Results 
suggested that women who were on SSRI treatment tended to be smokers, more obese, often 
developed preeclampsia, and had a shorter gestational length which tended to result in a preterm 
delivery. The CRH serum concentration was also increased at 16-20 weeks gestation but did not 
differ significantly in levels depending on SSRI. In comparison to the untreated, undepressed 
women, there were less pregnancy complications with noticeably lower CRH serum 
concentrations. The women with untreated depression did not have differing CRH serum 
concentrations compared to controls (Hannerfors et al., 2015).  
 An observational prospective comparative cohort study completed in 2012 by Klieger-
Grossmann et al. (2012) sought to evaluate the effects of escitalopram during pregnancy. Study 
participants included 6,582 mothers, of which 298 who reported use of an antidepressant during 
pregnancy (Klieger-Grossman et al., 2012). This study also evaluated which antidepressants 
were used, which included SSRIs as number one (3.8%) with bupropion second most commonly 
used (0.7%). Data was collected from 1998-2005 from women with a mean age of 33.1 +/- 2.3 
years and at the beginning of the cohort study were all taking escitalopram before becoming 
pregnant.  
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Of the two hundred and thirteen infants born to mothers taking escitalopram, 81% were 
live births, 15% were spontaneous abortions, 1.7% (3) stillbirths, 11% (19) premature births, and 
1.7% (3) had a major malformation upon delivery. It was also found that the rate of low birth 
weight, less than 2500 grams, was higher in escitalopram-exposed infants (9.9%) when 
compared to infants exposed to other antidepressants (3.6%) which resulted in P=.038 and non-
teratogen exposure (2.1%) with P=.003 (Klieger-Grossman et al., 2012). The study found no 
differences in incidence of infant malformation, premature birth rates, stillbirths, or Neonatal 
Intensive Care (NICU) admissions. The last noticeable research results found that spontaneous 
abortions were almost twice as frequent in both the escitalopram and other antidepressant groups 
when compared to the control group. The escitalopram resulted in 15% spontaneous abortions 
and other antidepressants were 16%, whereas the control group only experienced 8.5% 
spontaneous abortions (Klieger-Grossman et al., 2012). 
In a population based cohort study completed by Rai et al. (2017), research was focused 
on finding if a correlation exists between antidepressant use and autism in offspring in Sweden. 
Specifically, the study was designed to evaluate the use of antidepressants in pregnancy by the 
mother. Data was collected from 2001-2011 from the Stockholm youth cohort for ages 0-17 who 
lived in Stockholm County at the time (longer than four years). Children under four years of age 
were excluded due to less reliability for a true autism diagnosis as well as those children who 
were not linked to the medical birth register or who were not linked to their biological mothers 
(Rai et al., 2017).  
The results of the study found that of the 3,342 children who were exposed to 
antidepressant medications during pregnancy, 136 (4.1%) were diagnosed with autism. In the 
comparison group, there were 12,325 children whose mother had a psychiatric disorder as 
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diagnosed by ICD-9 and ICD-10 codes but did not take antidepressants during pregnancy. 
Within this control group, 353 (2.9%) of children were diagnosed with autism. Finally, the 
control group contained 238,943 children whose mothers had no record of psychiatric disorder or 
use of antidepressants during pregnancy, with a correlation of 4,889 (2.1%) of children 
diagnosed with autism. With this statistical evidence, it was found that exposure to 
antidepressants during pregnancy increased the risk of a diagnosis of autism in children 
compared to children not exposed, specifically for the diagnosis of autism without an intellectual 
disability with an odds ratio of 1.57 and confidence interval of 1.21 to 2.04 (Rai et al., 2017). 
Although there is no numerical data attached, the study also found that when these results were 
categorized into SSRI versus non-SSRI antidepressants, the risk of autism in offspring seemed to 
be similar for both groups (Rai et al., 2017). 
 A study published in 2009 evaluated the placental transfer of SSRI and SNRI 
antidepressants along with neonatal effects by authors Rampono et al. This prospective 
observation study included 75 pregnant women recruited at 18-32 weeks gestation. Exclusions 
applied were any known substance abuser and those who used any medication known to cause 
altered infant behavior. Of the 75 participants, 30 did not use antidepressants and were placed 
within the control group. Forty-five women were placed in the treatment group and were using 
SSRI (27 women) or SNRI (venlafaxine only) antidepressants.  
The results of the study found that when tested at delivery, distribution of metabolites and 
drug in the cord/maternal serum were high in the SSRI's escitalopram, fluoxetine, and 
fluvoxamine (0.7-0.86 as the medial values) but lower in the SSRI sertraline, N-
desmethylsertraline, and paroxetine (medial values of 0.36, 0.4, and 0.15, respectively). In 3-day-
old infants, SSRI concentrations were lower than cord serum (range 12-65%). SNRI 
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(venlafaxine) median concentrations at 3 days was 70%. Within the control group, babies not 
exposed to antidepressants tended to be born at a later median gestational age of 40 weeks and 
longer average length 51 centimeters (cm) versus those exposed to antidepressants averaging 39 
weeks at birth and 49 cm in length. These results classified as a significant difference (Rampono 
et al., 2009). However, there were no significant differences in obstetric outcomes or neonatal 
outcomes including Apgar scores, weight, resuscitation, gender, or head circumference. 
Brazelton Neonatal Behavioral Assessment Scale (BNBAS) cluster scores varied significantly 
between case and controls in areas of habituation, social-interactive, motor, and autonomic 
clusters (p<0.05) which suggests less optimal functioning in infants exposed to antidepressant 
medications during pregnancy (Rampono et al., 2009). 
As explained above, Wisner et al. (2009) also evaluated the fetal effects of SSRI 
exposure during pregnancy by assessing neonatal outcomes. Outcomes of the research focused 
on neonatal effects including, “Minor physical anomalies, maternal weight gain, infant birth 
weight, pregnancy duration, and neonatal characteristics” (Wisner et al., 2009, page 559). 
Results in this category of data found that of the 203 infants born, 30 (15%) had three or more 
physical malformations. However, depression, first-trimester nor continuous SSRI exposure 
showed any significant increase in proportion of infants with three or more anomalies. There 
were no major physical malformations observed in any of the infants. Neonatal birth weight 
(below 10th or above 90th percentile for gestational age), birth length, and head circumference did 
not differ across comparison groups. When comparing rate of preterm deliveries, both the group 
with continuous SSRI exposure and the group with continuous MDD resulted in over 20% of 
infants delivered preterm. In the other groups, preterm birth rates were between 4-9%. When 
adjusting for age and African American race, an increased relationship was found with 
TREATING PERI AND POSTNATAL DEPRESSION AND ANXIETY 22 
 
continuous SSRI exposure. In the adaptation category, there were no differences between vaginal 
versus surgical delivery rates, nor was there a difference in NICU admission rates (Wisner et al., 
2009). 
Theme C: antidepressant pharmacotherapy effects during lactation 
 A pooled research analysis conducted by Weissman et al. (2004) studied the plasma level 
transfer of SSRI medications from breastmilk to infants. This study included data collected from 
MEDLINE, Current Contents, Biological Abstracts, and PsycINFO beginning from 1996 and 
continuing through 2002 (Weissman et al., 2004). The results of this data collection and analysis 
found interesting correlations between different SSRI medications used in lactating mothers. 
First, results showed that fluoxetine use in breastfeeding mothers produced the highest serum 
percentage of 22% in infants as well as the highest mean standardized level. Citalopram was also 
found to produce higher infant serum levels. Paroxetine was the next SSRI to be elevated in 
infant serum, with one out of twenty-four studied infants resulting in an elevated portion level. 
These three SSRI’s were found to have the highest portion of medication transferred from 
mother to infant through breastmilk. The study also found that infants who were exposed to 
nortriptyline, paroxetine (except for the one infant stated above) and sertraline seem unlikely to 
develop elevated plasma levels from breastfeeding (Weissman et al., 2004).  
 Theme D: non-pharmacotherapy treatment efficacy 
 A study completed by Alder, Urech, Fink, Bitzer, and Hoesli (2011) in a quasi-
experimental trial sought to compare the effects of a single relaxation session with women 
experiencing high and low levels of anxiety in their third trimester of pregnancy. Before and 
after the session, anxiety levels, hypothalamus-pituitary-adrenal (HPA) axis and sympathetic 
adrenal-medullary (SAM) system activity levels were evaluated. The participant sample size was 
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thirty-nine healthy pregnant women over age eighteen. Treatment of anxiety included 
progressive muscle relaxation (PMR), guided imagery (GI), and passive relaxation/quiet resting 
(PR). Levels of epinephrine, norepinephrine, cortisol, and ACTH were measured to compare 
endocrine reactivity during the relaxation experiment. Results found that for patients with high or 
low anxiety levels, negative affect did not benefit differently in either group. Both groups did 
self-rate their relaxation as higher after the relaxation procedure for all time points measured at 1 
minute, 10 minutes, and 20 minutes (Alder et al., 2011). Therefore, the relaxation procedure 
seems to benefit highly anxious women and low anxious women similarly. 
Another quasi-experimental trial performed by Salehi, Pourasqhar, Khalilian, and 
Shahhesseini (2016) specifically focused on comparing the effects on anxiety of group cognitive 
behavioral therapy (CBT) to interactive lectures (IL) for women during their first pregnancy. The 
setting of the study was in northern Iran and included nulliparous women in their second 
trimester of pregnancy. Exclusion criteria were set and followed, resulting in a sample size of 
thirty-four women in each group- the CBT and IL groups, with 38 women in the control group 
receiving only prenatal care. The CBT group received four group counseling sessions with two 
sessions per week led by a trained midwife, psychiatrist, and a co-therapist. The IL group also 
completed four lectures with two per week. The control group completed standard prenatal care. 
The results of the study found that the group CBT showed improvements in anxiety compared to 
both the control and IL groups (P<.001). There was no significant difference found between state 
anxiety levels (P=0.079) or trait anxiety levels (P=0.069) in CBT versus IL treatment options 
(Salehi et al., 2016).  
In another study completed by Van Lieshout, Yang, Haber, and Ferro (2017) assessed the 
effectiveness of group CBT in comparison to individualized CBT for women with perinatal 
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depression. The main outcome measured was the level of depressive symptoms as reported by 
the patient. The group CBT was conducted weekly with a two-hour timeslot. The study size was 
34 individuals divided into seven separate CBT groups. 59% of the patients were not taking an 
antidepressant medication at the beginning of the study. The EPDS, Beck Depression Inventory 
II (BDI-II), social support evaluated through the Social Provisions Scale (SPS) and the quality of 
partner relationships was assessed using the Dyadic Adjustment Scale (DAS), and the quality of 
mother-infant bonding was measured using the Postnatal Bonding Questionnaire (PBQ). The 
results were quite positive, with statistically significant improvement across all study outcomes. 
80% of women receiving the group CBT showed a clinically significant improvement in 
depressive symptoms over the 9-week therapy course. There were also improvements noted in 
social support, bonding between the mother and infant, and quality of the partner relationship 
(Van Lieshout et al., 2017).  
A Cochrane Review completed by Dennis, Ross, and Grigoriadis (2007) evaluated the 
effects of psychosocial and psychological treatment methods on mothers and their families 
during pregnancy to treat antenatal depression. The search included data collected from the 
Cochrane Trials Registers, MEDLINE, EMBASE, and CINAHL in which all published, 
unpublished, and ongoing randomized controlled trials were selected. The ongoing trials 
included preventative psychosocial or psychological interventions with the aim of treating 
antenatal depression. Quasi-randomized trials were excluded from the analysis. Participants of 
the study were pregnant women completing nonpharmacologic treatment of depression. One 
study was conducted in the United States with a participant number of thirty-eight women 
(Dennis et al., 2007). 
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Results of the review were focused the effects on the mother. Maternal outcomes were 
evaluated immediately post-treatment which found that interpersonal psychotherapy when 
compared to parenting education programs did have a decreased risk of depressive symptoms. 
Both the Clinical Global Impression Scale and the Hamilton Rating Scale for Depression were 
used, with relative risk (RR) measured of 0.46 (CI95 0.26-0.83) and 0.82 (CI95 0.65-1.03) 
respectively. However, the authors concluded in their recommendations that due to the presence 
of only one adequate psychological or psychosocial trial of “antenatal depression,” there is 
insufficient data to recommend that psychosocial interventions are superior to antidepressant 
medication treatment options (Dennis et al., 2007). 
 In summary, the review of literature has thoroughly evaluated the effectiveness of 
pharmacotherapy and, separately, the effects on both the fetus and the breastfeeding infant. 
Nonpharmacologic means of treatment have also been evaluated for effectiveness. Throughout 
the Discussion section below, further comparison of the current research will provide a focused 
view of the research questions. 
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Discussion 
Throughout this research, it was interesting to note first the similarity of the studies in 
regard to the prevalence of prenatal depression. The average prevalence of prenatal depression is 
close to 15% and during the postpartum time up to one year after delivery, the incidence increases 
to almost 20% (Van Lieshout et al., 2017). According to the recommended treatment options, both 
pharmacological methods and psychosocial interventions such as cognitive behavioral therapies 
are available for patients. Below is a focused comparison of the current research specifically 
pertaining to this project’s research questions. 
In the pregnant and breastfeeding population, what is the efficacy of antidepressant 
medication treatment for patients diagnosed with depression and/or anxiety? 
Although many studies are completed evaluating fetal effects of antidepressant 
medications, there is limited literature assessing the effectiveness of these medications during 
pregnancy. As stated above by Charlton et al. (2014), SSRI’s are commonly prescribed as the 
antidepressant of choice in pregnant women, but discontinuation of antidepressants continues to 
occur. In fact, results from the study found that at least 40% of the women discontinued their 
SSRI prescriptions during pregnancy. According to the data, prescription levels dropped from 
5.4% receiving an SSRI prescription prior to pregnancy to 2.3% of women receiving a 
prescription during pregnancy (Charlton et al., 2014).  The other study pertinent to antidepressant 
effectiveness was completed by Wisner et al. (2009) who did find that the treatment with SSRIs 
showed higher mean levels of functioning when compared to either depression group with no 
SSRI exposure. These results correspond as well to the findings of postnatal depression studies 
evaluating the efficacy of antidepressants. 
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In the spectrum of postpartum women, the randomized controlled trial completed by 
Sharp et al. (2010) showed that antidepressant therapy appeared to be more beneficial in a 
quicker time-frame when compared psychosocial therapies such as listening services for PND. 
Results from this study showed that antidepressant medication tended to improve depressive 
symptoms quicker than the listening sessions. When comparing baseline EPDS scores to four 
weeks of treatment, 45% of women had significantly improved with antidepressant medication 
and only 20% showed significant improvement with the active listening therapy. However, at 
eighteen weeks, 62% of women had responded in the antidepressant category compared to 51% 
of women in the listening category (Sharp et al., 2010). The eighteen-week evaluation suggests 
that with continued therapy, the psychosocial sessions do seem to show significant 
improvements with a closer similarity to antidepressant treatment. In the Cochrane Review 
conducted by Molyneaux et al. (2014), although the participant number was low and there were 
limited studies available, results did suggest quicker response and remission rates in postnatal 
depression when using SSRIs compared to the usual psychological or social support treatment 
options. These findings do seem to agree with the findings from Sharp et al. (2010). 
It is unfortunate that there is limited literature data available for this important topic. As 
common as it is to find research on antidepressant medications and effects, very few quality 
studies evaluate the psychological effects on the mother during pregnancy and in the postpartum 
stages. It would be beneficial if continued research assessed the responses of patients who are 
administered antidepressants throughout pregnancy and afterwards to evaluate the true benefit 
medications may have on psychological health. 
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In patients diagnosed with depression and/or anxiety, what are the fetal effects resulting 
from use of antidepressants during pregnancy? 
 As shown in the literature review above, there is a vast expanse of research available 
evaluating possible fetal effects from antidepressant medication exposure during pregnancy. 
Several studies sought to evaluate the qualities of placental transfer of medications, while other 
research assessed long-term effects such as motor control and autism correlations in children 
three years and older. Interestingly enough, the results of the various studies correlated in the fact 
that there were almost always noticeable clinical effects in offspring of mothers who used 
antidepressant medications during pregnancy. 
 First, the study completed by Handal et al. (2016) did show a slightly increased rate of 
fine motor impairment in children exposed to SSRI medication in utero compared with children 
not exposed. There also seemed to be an increased rate of delayed motor development in the 
SSRI exposure group when compared to controls (Handal et al., 2016). The other study 
evaluating long-term effects of antidepressant medication was completed in Sweden to assess the 
risk of autism in offspring. Rai et al. (2017) found that in the antidepressant exposure group, 
4.1% of children were diagnosed with autism. In the comparison group of offspring from 
mothers who had a psychiatric disorder with no antidepressant use, 2.9% of children were 
diagnosed with autism. In the control group of mothers with no psychiatric disorders and no 
antidepressant use, the rate of autism diagnoses in offspring was 2.1%. Specifically, the research 
showed that antidepressant exposure increased a child’s risk of diagnosed autism without an 
intellectual ability by an odds ratio of 1.57 (Rai et al., 2017). These two studies do agree and 
suggest that antidepressant medication use during pregnancy does have an increased risk of 
negatively affecting offspring when considering the risks of autism and motor control delays.  
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 Several studies within this literature review focused on the effects of prenatal 
antidepressant medication use in relation to neonatal outcomes at delivery. First, Klieger-
Grossman et al. (2012) evaluated SSRIs and bupropion use during pregnancy. Specifically, when 
studying escitalopram, results found that the rate of low birth weight (less than 2,500 grams) was 
9.9% in infants exposed to escitalopram compared to 3.6% low birth weight rates in infants 
exposed to other antidepressants. Spontaneous abortions were found to be almost two times as 
frequent in the escitalopram and other antidepressant groups compared to the control group. 
Fortunately, there were no other noticeable differences in infant malformations, premature birth 
rates, stillbirths, or NICU admissions (Klieger-Grossman et al., 2012).  Rampono et al. (2009) 
also tended to suggest that gestational age of infants and average length was different when 
comparing newborns exposed to antidepressants and those not. The control newborn group with 
no antidepressant exposure showed that the babies were born at an average gestational age of 40 
weeks with an average length of 51 cm. Compared to the infants with antidepressant exposure, 
gestational age at birth was 39 weeks with an average length of 49 cm. Both of these results did 
classify as a significant difference. Interestingly, this study also found that there were not 
significant differences noted in obstetric outcomes or neonatal outcomes which correlated with 
Klieger-Grossman et al. (2012). Further in the study data shows that there were differences in the 
newborns exposed to antidepressants in areas of habituation, social-interactive, motor, and 
autonomic clusters to suggest decreased optimal functioning (Rampono et al., 2009). Hannerfors 
et al. (2015) found that CRH serum levels in pregnant women on SSRIs were increased 
associated with increased prenatal complications when compared to depressed women with no 
antidepressant medication use, with both a lower CRH serum level and less complications. The 
CRH level in untreated, depressed women was similar to healthy pregnant women (2015).    
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 One study included in this research evaluated the effects of SSRIs and other 
antidepressant medications across the placenta during pregnancy and the effects on the fetus. 
Rampono et al. (2009) found that several SSRIs resulted in a higher level of metabolite and 
medication levels in the cord/maternal serum including escitalopram, fluoxetine, and 
fluvoxamine. The serum levels were less in the SSRIs sertraline, N-desmethylsertaline, and 
paroxetine being the lowest (Rampono et al., 2009). Although the serum levels were elevated 
and SSRI use was associated with earlier delivery dates and shorter average length when 
compared to the control group, it is difficult to evaluate what the specific effects of these 
elevated SSRI medication and metabolite cord serum levels have on the infant. 
In breastfeeding patients diagnosed with depression, are there effects caused from the 
transfer of antidepressant medications from mother to infant during lactation? 
 There is limited research in the field of infantile effects from antidepressant medication 
exposure during the time of breastfeeding. Although the research question is broad, it was 
difficult to find specific studies that assessed infantile effects; rather the studies tended to 
evaluate the transferable qualities of antidepressant medications from mother to infant. One 
pertinent study included in this research was completed by Weissman et al. (2004) which 
evaluated the plasma transfer of SSRI medications from breastmilk to infants. Fluoxetine was 
found to have the highest serum percentage and the highest mean standardized level in infants 
after exposure through breastmilk. Citalopram was found to produce the next-highest levels. 
Paroxetine was third highest in transfer of medication, with one infant out of twenty-four with a 
positive level. The SSRI medications nortriptyline, paroxetine (except for the one infant above), 
and sertraline did not show a high risk of developing increased plasma levels from breastmilk. 
Unfortunately, this study did not evaluate the effects of these elevated serum levels, so further 
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research remains to be done in regards to the short and long-term effects on infants who are 
exposed to antidepressant medications during lactation. 
In patients diagnosed with depression and/or anxiety during pregnancy and postpartum, 
what is the effectiveness of treatment options such as cognitive behavioral health therapy? 
The literature available on behavioral health opportunities for management and treatment 
of depression in pregnancy and postpartum is broad, with thorough data including the type of 
therapy used and patient-related scores of depression and anxiety pre and post treatment. There 
did seem to be a common theme throughout the results suggesting that behavioral therapy, whether 
it be a group therapy or individual/partner-specific therapy is beneficial to mothers, both in the 
prenatal and postpartum timeframe. One very important benefit of psychosocial treatment is that 
it does not incur any possible negative effects on the fetus during pregnancy, which is frequently 
chief concern for expecting and breastfeeding mothers. 
The research completed by Alder et al. (2011) found that a single relaxation session did 
seem to improve anxiety in pregnant women, but did not find a major difference of effect in highly 
anxious versus low anxiety women (Alder, et al., 2011). When considering the effects of CBT, 
several studies within this research project evaluated depression improvement both subjectively 
and objectively. Salehi et al. (2016) found that when comparing CBT to IL for women in their first 
pregnancy, CBT tended to have greater improvements in anxiety symptoms (Salehi et al., 2016). 
The study completed by Van Lieshout et al. (2017) went one step further and compared group 
CBT to individualized CBT. Results showed that both the group and individualized CBT showed 
significant improvement in patient symptoms, partner relationships, and mother-infant bonding 
(Van Lieshout et al., 2017). Van Lieshout et al. study results may suggest a safer method of 
depression treatment compared to pharmacological means and may still result in positive 
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improvement of depressive symptoms in pregnant and postpartum women. Both of these studies 
suggest that CBT is an effective option for treatment and management of anxiety and depression 
in pregnant women. In the review completed by Dennis et al. (2007), results showed that treatment 
of depression through interpersonal psychotherapy did have an increased benefit when compared 
to parenting education programs, but due to the limited data available, it was difficult for their 
conclusion to be complete because a comparison to antidepressant medication options was not 
included (Dennis et al., 2007). 
 When considering the above research findings and similarity of study results, the data 
seems to correlate and agree well. While there is a known advantage to antidepressant medication 
use, there are also recognized potential risks for the unborn infant throughout pregnancy and 
potentially during lactation. Also, as recognized above, there is research that suggests 
psychotherapy such as CBT which is proven to be beneficial for pregnant mothers as well as 
partners and possibly, the mother-infant bonding during postpartum. In the following section, there 
will be an evaluation of current practices compared to recent research in this challenging field of 
depression and anxiety during pregnancy and postpartum. 
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Application to Clinical Practice 
 As stated above in the Introduction, the standard of practice for the management of 
depression and anxiety in adults is antidepressant medication and CBT, which have both been 
shown to improve depression symptoms (National Guideline Clearinghouse, 2012). It is common 
for antidepressant medication to be prescribed during both pregnancy and postpartum because of 
the quicker response time and effectiveness. Other frequently used methods of treatment include 
psychosocial and behavioral therapy interventions, which are also included in top 
recommendations for treatment of depression and anxiety. 
When evaluating current practice techniques for treating prenatal and postnatal 
depression and anxiety, several aspects of care must be considered. First, is the treatment plan 
going to be effective for the patient and will her symptoms improve? When considering this 
question, this literature review research tends to be in agreement that antidepressant medication, 
especially SSRIs, appears to have a quicker response rate in symptom improvement compared to 
nonpharmacologic methods such as CBT. When compared to symptom control of the anxiety 
and depression aspects of MDD, antidepressant medication has been shown to work within four 
weeks, whereas the psychosocial treatment methods seem to take longer for improvement, but 
then reach similar response rates after a longer period of time (Sharp et al., 2010). This evidence 
does agree with current recommendations that antidepressant medications are effective in 
treating depression and anxiety in relation to pregnancy and postpartum. For a woman not 
wishing to begin medication therapy for her depression or anxiety symptoms, both group and 
individual CBT sessions have been shown to provide benefits as well (Salehi et al., 2016).  
The second question to consider when determining a plan of care for a pregnant or 
breastfeeding woman with depression is if the method of treatment will affect the growing fetus/ 
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newborn infant in terms of delivery and development long-term. The research stated above in 
this literature review does agree that the drug and metabolites are passed to the fetus through the 
bloodstream and to the infant through breastmilk. The research tends to agree that use of 
antidepressant medications have an increased risk of an earlier delivery and smaller infants, but 
do not seem to change the maternal or neonatal outcomes during delivery. There does, however, 
appear to be long-term effects in offspring exposed to antidepressant medications in pregnancy. 
Unfortunately, the effects of these medications in breastmilk has not yet been evaluated 
thoroughly to understand what the long-term results may be. Further research remains to be 
completed in this area. 
In the clinical setting, because research continues to suggest that both pharmacologic and 
nonpharmacologic methods of treatment for depression and anxiety are beneficial, the decision 
to begin antidepressant medication or psychosocial therapy must continue to be a discussion for 
the patient and practitioner. Considerations such as severity of symptoms, risk to the fetus or 
infant health, and long-term response rates of the treatment options should be evaluated. Several 
other aspects of the treatment plan that also play an important role in a patient’s decision is the 
cost of the possible treatments and the availability of psychosocial interventions.  
In conclusion, because depression and anxiety continue to be present in pregnancy and 
the postpartum time, medical recommendations for treatment and management need to be 
cognizant of both maternal symptom management and the fetal/breastfeeding infant effects.  
Through the evidence shown above in the literature review, while both medications and 
psychosocial treatment benefit the mother, current guidelines may need to be adjusted to better 
preserve the safety of the children exposed to antidepressant medications. As research continues 
to be ongoing in this topic of prenatal and postnatal mental health, practice standards may change 
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to ensure the safety of the fetus/infant is maintained while the mother is receiving appropriate 
care for her psychological well-being.  
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